Open Access

EDITORIAL

Leonard G. Gomella
Canadian Journal of Urology, Vol.31, No.3, pp. 11864-11866, 2024
Abstract This article has no abstract. More >

View

34

Download

33

Open Access

LETTER

Jenelle Foote¹, Sakshi Shiromani², Nieraj Jain²
Canadian Journal of Urology, Vol.31, No.3, pp. 11867-11868, 2024
Abstract This article has no abstract. More >

View

35

Download

36

Open Access

LETTER

Jeffrey G. Proctor
Canadian Journal of Urology, Vol.31, No.3, pp. 11869-11870, 2024
Abstract This article has no abstract. More >

View

31

Download

37

Open Access

BOOK REVIEW

Rene Sotelo
Canadian Journal of Urology, Vol.31, No.3, pp. 11871-11871, 2024
Abstract This article has no abstract. More >

View

31

Download

33

Open Access

LEGENDS IN UROLOGY

Serigne-Magueye Gueye
Canadian Journal of Urology, Vol.31, No.3, pp. 11872-11874, 2024
Abstract This article has no abstract. More >

View

30

Download

39

Open Access

ARTICLE

Evangelia Vlachou¹, Burles Avner Johnson 3rd^1,2, Elizabeth Guancial³, Kara A. Lombardo^1,2,4, Jean Hoffman-Censits^1,2
Canadian Journal of Urology, Vol.31, No.3, pp. 11875-11879, 2024
Abstract Introduction: Immune checkpoint inhibitors (ICIs) are approved for advanced urothelial cancer alone and as first line in combination with enfortumab vedotin. Platinum based chemotherapy which is another frontline choice is often not a treatment option for older patients due to comorbidities that increase with age. Despite ICIs being better tolerated compared to traditional chemotherapy little is known about their efficacy and toxicity in patients ≥ 90 years due to the rarity of this population in clinical trials. Our objective was to analyze the efficacy and toxicity of immune checkpoint inhibitors in patients ≥ 90 years.
Materials and… More >

View

42

Download

37

Open Access

ARTICLE

Nader A. Shayegh¹, Danae Byer¹, Yasmine Griffiths¹, Pamela W. Coleman², Leslie A. Deane², Jeremy Tonkin²
Canadian Journal of Urology, Vol.31, No.3, pp. 11880-11885, 2024
Abstract This article has no abstract. More >

View

33

Download

32

Open Access

ARTICLE

Nikola C. Teslovich¹, Peter Elliott², Christopher S. Elliott²
Canadian Journal of Urology, Vol.31, No.3, pp. 11886-11891, 2024
Abstract Introduction: To define the smallest prostate needle biopsy (PNB) template necessary for accurate tissue diagnosis in men with markedly elevated PSA while decreasing procedural morbidity.
Materials and methods: We performed a chart review of 80 men presenting with a newly elevated PSA > 100 ng/mL who underwent biopsy (PNB or metastatic site). For patients who underwent a full 12-core biopsy, simulated templates of 2- to 10-cores were generated by randomly drawing subsets of biopsies from their full-template findings. Templates were iterated to randomize core location and generate theoretical smaller template outcomes. Simulated biopsy results were compared to… More >

View

34

Download

29

Open Access

ARTICLE

Shridhar C. Ghagane^1,3, Shadab Rangrez³, R.B. Nerli^2,3, Madhukar L. Thakur^4,6, Leonard G. Gomella^5,6
Canadian Journal of Urology, Vol.31, No.3, pp. 11892-11896, 2024
Abstract Introduction: Prostate cancer is the second most common malignancy in men worldwide. Genomic VPAC receptors are expressed on malignant prostate cancer cells and can be targeted and imaged optically by a peptide labeled fluorophore. The objective of our study was to assess the feasibility of detecting cancer of the prostate using a voided urine sample.
Materials and methods: Patients ≥ 40 years old, with lower urinary tract symptoms and serum PSA > 4 ng/ mL formed the study group. The first 50 mL of voided urine sample was collected and processed. The cells that were shed in… More >

View

35

Download

39

Open Access

COMMENTARY

Stephen E. Strup
Canadian Journal of Urology, Vol.31, No.3, pp. 11897-11897, 2024
Abstract This article has no abstract. More >

View

38

Download

29

Open Access

ARTICLE

Jack Considine¹, Kyle O'Hollaren¹, Codrut Radoiu¹, Raghav Madan¹, Aron Liaw^1,2, Nivedita Dhar^2,3
Canadian Journal of Urology, Vol.31, No.3, pp. 11898-11903, 2024
Abstract Introduction: Interstitial cystitis/bladder pain syndrome (IC/BPS) is characterized by chronic pelvic pain and usually accompanies lower urinary tract symptoms. We have previously reported that amniotic bladder therapy (ABT) provides symptomatic improvement in refractory IC/BPS patients for up to 3 months. Herein, we evaluated the durability of ABT up to 6 months.
Materials and methods: Consecutive IC/BPS patients received intra-detrusor injections of 100 mg micronized amniotic membrane. Clinical evaluation and patient reported outcome measurements including Interstitial Cystitis Symptom Index (ICSI), Interstitial Cystitis Problem Index (ICPI), Bladder Pain/ Interstitial Cystitis Symptom Score (BPIC-SS) and Overactive Bladder Assessment Tool (OAB)… More >

View

31

Download

32

Open Access

HOW I DO IT

Bruce M. Gao, Seyedamirvala Saadat, Edward J. H. Choi, James Jiang, Akhil K. Das
Canadian Journal of Urology, Vol.31, No.3, pp. 11904-11907, 2024
Abstract Holmium enucleation of the prostate (HoLEP) is a gold standard, size-independent surgical treatment for benign prostatic hyperplasia (BPH) distinguished for its efficacy in tissue removal, shorter catheterization durations, lower transfusion rates, and decreased hospital stays when compared to transurethral resection of the prostate (TURP). The objective of this article is to demonstrate the step-by-step procedure of holmium laser cystolitholapaxy and enucleation of the prostate for BPH, emphasizing a top-down modified two-lobe technique with early apical release which enhances visualization and irrigation flow during the enucleation process. More >

View

32

Download

36

Open Access

RESIDENT’S CORNER

Maria J. D’Amico¹, Jennifer A. Hagerty²
Canadian Journal of Urology, Vol.31, No.3, pp. 11908-11910, 2024
Abstract Urethral injuries are rare among the pediatric population, and the majority occur after trauma. This is the case of an eight-year-old female with complete proximal urethral disruption and ruptured bladder neck without pelvic fracture after a motor vehicle crash. After the accident, her bladder neck was reapproximated and a suprapubic tube was placed. Three months later, she underwent reconstruction for a bladder neck closure and appendicovesicostomy. In managing these patients, focus should first be directed at achieving a safe means of urinary drainage, and next to repair the lower urinary tract to maximize continence and More >

View

35

Download

31

Open Access

RESIDENT’S CORNER

Suraj Pursnani, Necole M. Streeper
Canadian Journal of Urology, Vol.31, No.3, pp. 11911-11913, 2024
Abstract Drug-induced nephrolithiasis represents only 1%-2% of stone cases. Here we focus on drugs capable of crystallizing and forming stone, specifically phenazopyridine (Pyridium/Azo). This is a case of a patient who presented with a stone conglomerate in the right proximal ureter and underwent definitive treatment. Interestingly, the stone had a purple hue with FTIR spectroscopy showing stone composition of calcium oxalate (monohydrate and dihydrate) and a material resembling phenazopyridine. We retrospectively learned that she used multiple extended courses of phenazopyridine over 3 months. More >

View

34

Download

32